Gilead's Trodelvy Secures First-Line EU Approval for Metastatic Triple-Negative Breast Cancer
Event summary
- European Commission approves Trodelvy as first-line treatment for metastatic triple-negative breast cancer (TNBC) in patients not eligible for PD-1/PD-L1 inhibitors.
- Approval based on Phase 3 ASCENT-03 study showing 38% reduced risk of disease progression or death compared to standard chemotherapy.
- Gilead seeks additional EU approvals for Trodelvy in combination with Keytruda for PD-L1 positive TNBC patients.
- Trodelvy is the first antibody-drug conjugate (ADC) approved for first-line metastatic TNBC in the European Union.
The big picture
This approval solidifies Trodelvy's role in treating one of the most aggressive forms of breast cancer, addressing an unmet need for patients who lack viable first-line options. Gilead's strategic focus on expanding Trodelvy's indications and combinations with other therapies like Keytruda positions it to dominate the TNBC treatment landscape. The approval also underscores the growing importance of antibody-drug conjugates in oncology.
What we're watching
- Regulatory Momentum
- Whether Gilead can secure similar approvals in the U.S. and other regions for Trodelvy's expanded indications.
- Commercial Strategy
- How Gilead positions Trodelvy as a backbone treatment across PD-L1 status in first-line metastatic TNBC.
- Pipeline Expansion
- The pace at which Gilead advances Trodelvy into other tumor types, including small cell lung cancer and gynecologic cancers.